Rice and MD Anderson scientists are researching new methods for treating brain cancer by overcoming the blood-brain barrier. Photo via Getty Images.

Rice University chemist Han Xiao, who also serves as director of the university’s Synthesis X Center, and cancer biologist Dihua Yu of The University of Texas MD Anderson Cancer Center have received a three-year, $1.5 million grant from the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation.

The funding will allow them to continue their research on treating brain metastasis by overcoming the blood-brain barrier, or the BBB, according to a news release.

Brain metastasis is the leading form of brain cancer, with survival rates below 20 percent within a year of diagnosis, according to the National Library of Medicine. It commonly originates from breast, lung and melanoma cancers.

The BBB typically acts as a protective barrier for the brain. However, it prevents most drugs from being able to directly reach the brain. According to Rice, only 2 percent of FDA-approved small molecule drugs can penetrate the BBB, limiting treatment options.

Xiao and Yu’s approach to dealing with the BBB includes a light-induced brain delivery (LIBD) platform. The advanced system employs nanoparticles that are embedded with a near-infrared dye for the transport of therapeutic agents across the BBB. The research will evaluate the LIBD’s ability to improve the delivery of small-molecule drugs and biological therapies. Some therapies have shown potential for reducing cancer growth in laboratory studies, but they have struggled due to limited BBB penetration in animal models.

“Our LIBD platform represents a novel strategy for delivering drugs to the brain with precision and efficiency,” Xiao said in a news release. “This technology could not only improve outcomes for brain metastasis patients but also pave the way for treating other neurological diseases.”

The Kleberg Foundation looks for groundbreaking medical research proposals from leading institutions that focus on “innovative basic and applied biological research that advances scientific knowledge and human health” according to the foundation.

“This research is a testament to the power of collaboration and innovation,” Xiao said in a news release. “Together, we’re pushing the boundaries of what’s possible in treating brain metastasis and beyond.”

Rice launched the Synthesis X Center, or Synth X, last spring. It was born out of what started about eight years ago as informal meetings between Xiao's research group and others from the Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center. It aims to turn fundamental research into clinical applications through collaboration.

“This collaboration builds on the strengths of both research teams,” Xiao said in the release. “By combining SynthX Center's expertise in chemistry with Dr. Yu's expertise in cancer biology and brain metastases, we aim to create a transformative solution.”

The funds were awarded to Han Xiao, a scientist at Rice University.

Houston chemist lands $2M NIH grant for cancer treatment research

future of cellular health

A Rice University chemist has landed a $2 million grant from the National Institute of Health for his work that aims to reprogram the genetic code and explore the role certain cells play in causing diseases like cancer and neurological disorders.

The funds were awarded to Han Xiao, the Norman Hackerman-Welch Young Investigator, associate professor of chemistry, from the NIH's Maximizing Investigators’ Research Award (MIRA) program, which supports medically focused laboratories.

Xiao will use the five-year grant to develop noncanonical amino acids (ncAAs) with diverse properties to help build proteins, according to a statement from Rice. He and his team will then use the ncAAs to explore the vivo sensors for enzymes involved in posttranslational modifications (PTMs), which play a role in the development of cancers and neurological disorders. Additionally, the team will look to develop a way to detect these enzymes in living organisms in real-time rather than in a lab.

“This innovative approach could revolutionize how we understand and control cellular functions,” Xiao said in the statement.

According to Rice, these developments could have major implications for the way diseases are treated, specifically for epigenetic inhibitors that are used to treat cancer.

Xiao helped lead the charge to launch Rice's new Synthesis X Center this spring. The center, which was born out of informal meetings between Xio's lab and others from the Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center at the Baylor College of Medicine, aims to improve cancer outcomes by turning fundamental research into clinical applications.

They will build upon annual retreats, in which investigators can share unpublished findings, and also plan to host a national conference, the first slated for this fall titled "Synthetic Innovations Towards a Cure for Cancer.”

Researchers at the new SynthX Center will aim to turn fundamental research into clinical applications and make precision adjustments to drug properties and molecules. Photo via Rice University

Houston organizations launch collaborative center to boost cancer outcomes

new to HOU

Rice University's new Synthesis X Center officially launched last month to bring together experts in cancer care and chemistry.

The center was born out of what started about seven years ago as informal meetings between Rice chemist Han Xiao's research group and others from the Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center at the Baylor College of Medicine. The level of collaboration between the two teams has grown significantly over the years, and monthly meetings now draw about 100 participants from across disciplines, fields and Houston-based organizations, according to a statement from Rice.

Researchers at the new SynthX Center will aim to turn fundamental research into clinical applications and make precision adjustments to drug properties and molecules. It will focus on improving cancer outcomes by looking at an array of factors, including prevention and detection, immunotherapies, the use of artificial intelligence to speed drug discovery and development, and several other topics.

"At Rice, we are strong on the fundamental side of research in organic chemistry, chemical biology, bioengineering and nanomaterials,” Xiao says in the statement. “Starting at the laboratory bench, we can synthesize therapeutic molecules and proteins with atom-level precision, offering immense potential for real-world applications at the bedside ... But the clinicians and fundamental researchers don’t have a lot of time to talk and to exchange ideas, so SynthX wants to serve as the bridge and help make these connections.”

SynthX plans to issue its first merit-based seed grants to teams with representatives from Baylor and Rice this month.

With this recognition from Rice, the teams from Xiao's lab and the TMC will also be able to expand and formalize their programs. They will build upon annual retreats, in which investigators can share unpublished findings, and also plan to host a national conference, the first slated for this fall titled "Synthetic Innovations Towards a Cure for Cancer.”

“I am confident that the SynthX Center will be a great resource for both students and faculty who seek to translate discoveries from fundamental chemical research into medical applications that improve people’s lives,” Thomas Killian, dean of the Wiess School of Natural Sciences, says in the release.

Rice announced that it had invested in four other research centers along with SynthX last month. The other centers include the Center for Coastal Futures and Adaptive Resilience, the Center for Environmental Studies, the Center for Latin American and Latinx Studies and the Rice Center for Nanoscale Imaging Sciences.

Earlier this year, Rice also announced its first-ever recipients of its One Small Step Grant program, funded by its Office of Innovation. The program will provide funding to faculty working on "promising projects with commercial potential," according to the website.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.

New accelerator for AI startups to launch at Houston's Ion this spring

The Collectiv Foundation and Rice University have established a sports, health and wellness startup accelerator at the Ion District’s Collectiv, a sports-focused venture capital platform.

The AI Native Dual-Use Sports, Health & Wellness Accelerator, scheduled to formally launch in March, will back early-stage startups developing AI for the sports, health and wellness markets. Accelerator participants will gain access to a host of opportunities with:

  • Mentors
  • Advisers
  • Pro sports teams and leagues
  • University athletics programs
  • Health care systems
  • Corporate partners
  • VC firms
  • Pilot projects
  • University-based entrepreneurship and business initiatives

Accelerator participants will focus on sports tech verticals inlcuding performance and health, fan experience and media platforms, data and analytics, and infrastructure.

“Houston is quickly becoming one of the most important innovation hubs at the intersection of sports, health, and AI,” Ashley DeWalt, co-founder and managing partner of The Collectiv and founder of The Collectiv Foundation, said in a news release.

“By launching this platform with Rice University in the Ion District,” he added, “we are building a category-defining acceleration engine that gives founders access to world-class research, global sports properties, hospital systems, and venture capital. This is about turning sports-validated technology into globally scalable companies at a moment when the world’s attention is converging on Houston ahead of the 2026 World Cup.”

The Collectiv accelerator will draw on expertise from organizations such as the Rice-Houston Methodist Center for Human Performance, Rice Brain Institute, Rice Gateway Project and the Texas Medical Center.

“The combination of Rice University’s research leadership, Houston’s unmatched health ecosystem, and The Collectiv’s operator-driven investment platform creates a powerful acceleration engine,” Blair Garrou, co-founder and managing partner of the Mercury Fund VC firm and a senior adviser for The Collectiv, added in the release.

Additional details on programming, partners and application timelines are expected to be announced in the coming weeks.

4 Houston-area schools excel with best online degree programs in U.S.

Top of the Class

Four Houston-area universities have earned well-deserved recognition in U.S. News & World Report's just-released rankings of the Best Online Programs for 2026.

The annual rankings offer insight into the best American universities for students seeking a flexible and affordable way to attain a higher education. In the 2026 edition, U.S. News analyzed nearly 1,850 online programs for bachelor's degrees and seven master's degree disciplines: MBA, business (non-MBA), criminal justice, education, engineering, information technology, and nursing.

Many of these local schools are also high achievers in U.S. News' separate rankings of the best grad schools.

Rice University tied with Texas A&M University in College Station for the No. 3 best online master's in information technology program in the U.S., and its online MBA program ranked No. 21 nationally.

The online master's in nursing program at The University of Texas Medical Branch in Galveston was the highest performing master's nursing degree in Texas, and it ranked No. 19 nationally.

Three different programs at The University of Houston were ranked among the top 100 nationwide:
  • No. 18 – Best online master's in education
  • No. 59 – Best online master's in business (non-MBA)
  • No. 89 – Best online bachelor's program
The University of Houston's Clear Lake campus ranked No. 65 nationally for its online master's in education program.

"Online education continues to be a vital path for professionals, parents, and service members seeking to advance their careers and broaden their knowledge with necessary flexibility," said U.S. News education managing editor LaMont Jones in a press release. "The 2026 Best Online Programs rankings are an essential tool for prospective students, providing rigorous, independent analysis to help them choose a high-quality program that aligns with their personal and professional goals."

A little farther outside Houston, two more universities – Sam Houston State University in Huntsville and Texas A&M University in College Station – stood out for their online degree programs.

Sam Houston State University

  • No. 5 – Best online master's in criminal justice
  • No. 30 – Best online master's in information technology
  • No. 36 – Best online master's in education
  • No. 77 – Best online bachelor's program
  • No. 96 – Best online master's in business (non-MBA)
Texas A&M University
  • No. 3 – Best online master's in information technology (tied with Rice)
  • No. 3 – Best online master's in business (non-MBA)
  • No. 8 – Best online master's in education
  • No. 9 – Best online master's in engineering
  • No. 11 – Best online bachelor's program
---

This article originally appeared on CultureMap.com.